Yan Luo, Müller Christa E
University of Bonn, Pharmaceutical Chemistry Poppelsdorf, Pharmaceutical Sciences, Bonn, Germany.
J Med Chem. 2004 Feb 12;47(4):1031-43. doi: 10.1021/jm0310030.
Many currently known antagonists for P2 purinergic receptors are anionic molecules bearing one or several phenylsulfonate groups. Among the P1 (adenosine) receptor antagonists, the xanthine phenylsulfonates are a potent class of compounds. Due to their high acidity, phenylsulfonates are negatively charged at physiologic pH values and do not easily penetrate cell membranes. The present study was aimed at developing lipophilic, perorally bioavailable prodrugs of sulfonates by converting them into chemically stable nitrophenyl esters. Initial stability tests at different pH values using nitrophenyl tosylates as model compounds showed that m-nitrophenyl esters were stable over a wide pH range, while the ortho and para isomers were less stable under strongly acidic or basic conditions. A series of m- and p-nitrophenyl esters of p-sulfophenylxanthine derivatives were synthesized as model compounds. The target xanthine derivatives were obtained in high yields by condensation of the appropriate 5,6-diaminouracils with 4-(nitrophenoxysulfonyl)benzoic acids in the presence of a carbodiimide, followed by ring closure with polyphosphoric acid trimethylsilyl ester. The chemical and enzymatic stability of the m-nitrophenyl esters was investigated in vitro by means of capillary electrophoresis. High stability in aqueous solution, in artificial gastric acid, and in serum was observed. However, compound 5d, used as a prototypic xanthine m-nitrophenylsulfonate, was hydrolyzed by rat liver homogenate indicating an enzymatic pathway of hydrolysis. Thus, nitrophenyl esters of sulfonic acids have a potential as peroral prodrugs of drugs bearing a sulfonate group. The nitrophenyl esters of sulfophenylxanthines were additionally investigated for their adenosine receptor affinities. They showed high affinity at A(1), A(2A), and A(2B), but not at A(3) ARs. One of the most potent compounds was 1-propyl-8-[4-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine (9d), a mixed A(1)/A(2B) antagonist (K(i)A(1) 3.6 nM, K(i)A(2B) 5.4 nM) selective versus the other subtypes. As a further result of this study, the m-nitrophenoxy group was found to be a suitable protecting group for sulfonates in organic synthesis due to its high lipophilicity and stability; it can be split off under strongly basic conditions. This new protection strategy allowed for the upscaling of the synthesis of 1-propyl-8-p-sulfophenylxanthine (PSB-1115), a selective A(2B) antagonist.
目前已知的许多P2嘌呤能受体拮抗剂都是带有一个或多个苯磺酸盐基团的阴离子分子。在P1(腺苷)受体拮抗剂中,黄嘌呤苯磺酸盐是一类有效的化合物。由于其高酸度,苯磺酸盐在生理pH值下带负电荷,不易穿透细胞膜。本研究旨在通过将磺酸盐转化为化学稳定的硝基苯酯来开发亲脂性、口服生物可利用的前药。使用对甲苯磺酸硝基苯酯作为模型化合物在不同pH值下进行的初步稳定性测试表明,间硝基苯酯在很宽的pH范围内稳定,而邻位和对位异构体在强酸性或碱性条件下稳定性较差。合成了一系列对磺基苯黄嘌呤衍生物的间硝基苯酯和对硝基苯酯作为模型化合物。通过在碳二亚胺存在下将适当的5,6-二氨基尿嘧啶与4-(硝基苯氧基磺酰基)苯甲酸缩合,然后用多磷酸三甲基硅酯闭环,以高产率获得目标黄嘌呤衍生物。通过毛细管电泳在体外研究了间硝基苯酯的化学和酶稳定性。观察到在水溶液、人工胃酸和血清中具有高稳定性。然而,用作原型黄嘌呤间硝基苯磺酸盐的化合物5d被大鼠肝匀浆水解,表明存在酶促水解途径。因此,磺酸的硝基苯酯有潜力作为带有磺酸盐基团药物的口服前药。还研究了对磺基苯黄嘌呤的硝基苯酯对腺苷受体的亲和力。它们在A(1)、A(2A)和A(2B)受体上显示出高亲和力,但在A(3)腺苷受体上没有。最有效的化合物之一是1-丙基-8-[4-[[对硝基苯氧基]磺酰基]苯基]黄嘌呤(9d),它是一种混合的A(1)/A(2B)拮抗剂(K(i)A(1) 3.6 nM,K(i)A(2B) 5.4 nM),对其他亚型具有选择性。作为本研究的另一个结果,发现间硝基苯氧基由于其高亲脂性和稳定性,是有机合成中磺酸盐的合适保护基团;它可以在强碱性条件下裂解。这种新的保护策略使得选择性A(2B)拮抗剂1-丙基-8-对磺基苯黄嘌呤(PSB-1115)的合成得以扩大规模。